January 2000
CMAJ: Canadian Medical Association Journal;1/11/2000, Vol. 162 Issue 1, p100
Academic Journal
Offers medical news briefs for January 11, 2000, and the citations for journals in which they were published. Thalidomide as a treatment for multiple myeloma; Topical gel that stimulates blood flow in the hands of patients with severe Raynaud's syndrome; Research showing how prion proteins causing transmissible spongiform encephalopathies are replicated and passed on by follicular dendritic cells, antigen-presenting cells found in the germinal centers of lymph nodes.


Related Articles

  • Induced Vasodilation as Treatment for Raynaud's Disease. Jobe, Jared B.; Sampson, James B.; Roberts, Donald E.; Beetham Jr., William P. // Annals of Internal Medicine;Nov82, Vol. 97 Issue 5, p706 

    Examines the efficacy of induced vasodilation as a treatment of idiopathic Raynaud's disease. Information on Raynaud's disease; Details of several medical approach for Raynaud's disease; Alternative method for the counter-conditioning of the autonomic nervous system; Clinical features of...

  • New oral anticoagulant and cancer drug believed to be firsts. McCann, Jean // Drug Topics;1/3/2000, Vol. 144 Issue 1, p34 

    Presents information on anticoagulant and cancer drugs. Introduction of H376/95 by AstraZeneca, an oral anticoagulant and ST1 571 by Novartis, an inhibitor; Comeback of once-banned thalidomide for the treatment of leukemia; Results of medical studies regarding the drugs.

  • Thalidomide: An Overview of its Pharmacological Mechanisms of Action. Sampaio, Elizabeth P.; Carvalho, Daniel S.; Nery, Jose A. C.; Lopes, Ulisses G.; Sarno, Euzenir N. // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Feb2006, Vol. 5 Issue 1, p71 

    Novel discoveries in medicine have provided understanding of the mechanisms involved in the development and maintenance of pathologies, thereby leading to the identification of new therapeutic targets and consequently new drugs. Thalidomide, independently of its teratogenic effects, is one drug...

  • In brief.  // BMJ: British Medical Journal (International Edition);02/03/2001, Vol. 322 Issue 7281, p256 

    Offers various medical-related news briefs, as of February 3, 2001. Report that England's House of Lords voted to continue the sale of over-the-counter emergency contraceptive pills; How women who have used hormone replacement therapy (HRT) retain more teeth than women who have not; Use of...

  • Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma. Singh, Anurag; Gajra, Ajeet // Cardiovascular & Hematological Agents in Medicinal Chemistry;2011, Vol. 9 Issue 1, p7 

    No abstract available.

  • Multisystem Langerhans Cell Histiocytosis: Successful Treatment with Thalidomide. Broekaert, Sigrid M. C.; Metzler, Gisela; Burgdorf, Walter; Röcken, Martin; Martin Schaller // American Journal of Clinical Dermatology;2007, Vol. 8 Issue 5, p311 

    A 57-year-old woman presented with a 1-year history of non-healing inguinal and perianal ulcers as well as a 2-year history of polydipsia. The clinical picture and histology suggested Langerhans cell histiocytosis, which was confirmed by immunohistochemistry and electron microscopy. Magnetic...

  • Thalidamide for IPF-associated cough. Kardos, Peter // Thorax;Dec2013, Vol. 68 Issue 12, p1164 

    The article focuses on a randomized crossover trial at Johns Hopkins in Baltimore, Maryland, as of December 2013 which assessed the efficacy of thalidomide versus placebo on cough in patients with idiopathic pulmonary fibrosis.

  • Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. Kim, Kihyun; Kim, Seok; Voelter, Verena; Suh, Cheolwon; Yoon, Sung-Soo; Lee, Je-Jung; Kwak, Jae-Yong; Ryoo, Hun-Mo; Kim, Yang; Moon, Joon; Park, Seong; Kim, Sung-Hyun; Mun, Yeung-Chul; Kim, Jin; Eom, Hyeon-Seok; Jo, Deog-Yeon; Jun, Hyun; Kim, Ki-Hwan; Lee, Jeong-Ok; Lee, Jae // Annals of Hematology;Jan2014, Vol. 93 Issue 1, p113 

    We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not...

  • Thalidomide in Small Cell Lung Cancer: Wrong Drug or Wrong Disease? Rüegg, Curzio; Peters, Solange // JNCI: Journal of the National Cancer Institute;8/5/2009, Vol. 101 Issue 15, p1034 

    The authors discuss a placebo-controlled trial conducted by Lee and colleagues in small cell lung cancer (SCLC) combining thalidomide with carboplatin and etoposide chemotherapy. They discuss Pujol and collegues' phase III study in 2008 in which thalidomide was combined with cisplatin,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics